10results about How to "Suppressed expression level" patented technology

The invention is applicable to the technical field of biological pharmacy, and provides application of a novel nano drug-loading delivery system of exosome-loaded ginsenoside Rh2. The ginsenoside Rh2 and the MSC-derived exosome are subjected to blending ultrasonic treatment to realize exosome drug loading, and a novel Rh2-coated MSC-exo nano drug loading delivery system is synthesized. Animal experiments show that the Rh2 (at) MSC-exo novel nano drug-loading delivery system can be targeted to ectopic intimal lesions and has an inhibition effect; the expression level of an M1 type macrophage marker CD86 is enhanced, and the expression level of an M2 type macrophage marker CD206 is inhibited; the m6A level and the METTL3 expression level of ectopic endometrial tissues are reduced; according to the present invention, RNA-seq and MIP-seq sequencing is adopted to determine that WNT2 is the potential target of the Rh2 (at) MSC-exo novel nanometer drug loading delivery system affecting ectopic inner membrane m6A modification;

The invention discloses an application of a Piezo1 inhibitor in preparation of a medicine for treating necrotizing enterocolitis. The Piezo1 inhibitor can be applied in preparation of the medicine for treating the necrotizing enterocolitis. The Piezo1 inhibitor can also be applied to preparation of drugs for relieving NEC intestinal epithelial barrier injury. The Piezo1 inhibitor can also be applied to preparation of drugs for reducing calcium influx in intestinal epithelial cells and calcium / calmodulin dependent protein kinase activity. The application has the beneficial effects that the effect and mechanism of the Piezo1 for regulating and controlling the calcium ion influx and promoting the NEC severity degree by the calcium / calmodulin dependent protein kinase activity level are discussed for the first time from multiple aspects of animals, tissues, cells, molecules and the like, and the effect and mechanism of the activated intestinal epithelial cell Piezo1 in NEC inflammatory injury and barrier repair are clarified for the first time; the knockout of the gene can improve the NEC severity of mice, and a new intervention target is provided for clinical treatment.

The invention relates to the field of medicinal chemistry, in particular to a CDK6 / 9 dual inhibitor and a preparation method and application thereof.The CDK6 / 9 dual inhibitor has CDK6 and CDK9 inhibitory activity at the same time, has an inhibitory effect on abnormal hyperplasia of a psoriasis cell model and inflammatory factor disorder and has good safety and selectivity in a CDK family; the inhibitor can be used as a therapeutic drug for psoriasis dermatitis, psoriatic arthritis and other autoimmune diseases.

This invention discloses a cyclic nonapeptide with both anti-photoaging and antioxidant effects. The amino acid sequence of the cyclic nonapeptide is: cyclic (arginine-glycine-aspartic acid-serine-asparagine-lysine-valine-lysine-phenylalanine). The cyclic nonapeptide of this invention can effectively reduce deep photoaging caused by UVA and surface oxidative damage induced by UVB, thereby achieving comprehensive skin protection.

The present application discloses a targeted peptide modified beauty peptide composition, which is a complex composed of a targeting peptide and a beauty peptide covalently / non-covalently. The targeting peptide has a linear or cyclic peptide composed of 3 to 30 amino acids, including an RGD polypeptide targeting the cell surface integrin αvβ3, an Otx2 polypeptide targeting the cell surface chondroitin sulfate, or a transmembrane peptide targeting the cell interior. Beauty peptides include acetylated, fatty acid acylated or non-acylated active peptides commonly seen on the market that exert effects inside and outside cells. The targeted beauty peptide composition of the present invention does not affect the activity of beauty peptides, is used for skin makeup treatment, promotes cell surface aggregation or intracellular guidance of beauty peptides, increases the chance of beauty peptides binding to intracellular and extracellular receptors, and enhances the efficacy of beauty peptides, especially anti-oxidation, anti-aging, increases the collagen content of skin tissue, and repairs the keratin structure of skin cells. It has good application potential in the field of cosmetic raw materials.

The invention provides application of a Chinese redbud bark extract in preventing and treating inflammatory bowel diseases. Relates to the technical field of medicine. The kadsura root-bark extract is obtained by performing heating reflux twice and vacuum concentration drying on dried kadsura root-bark. The kadsura root-bark extract can prevent colon shortening, inhibit the expression level of myeloperoxidase (MPO) and improve the pathological structure of colon tissue so as to prevent and treat the inflammatory bowel disease, especially colitis, and is applied to preparation of drugs, food or health care products for preventing and treating the inflammatory bowel disease.

The invention relates to an application of a small molecule compound in preparation of anti-liver injury or anti-hepatic fibrosis drugs, the compound has a compound structure as shown in a formula I: # imgabs0 #, and cell experiments prove that the compound can inhibit secretion of LX-2 cell III type procollagen N-terminal peptide (PIIINP) and has a stable inhibition effect; the liver injury of HepG2 cells induced by acetaminophen (APAP) can be improved, the expression of liver fibrosis related genes and proteins can be inhibited, the migration of LX-2 cells can be inhibited, and the like. In addition, the compounds exhibit low toxicity to hepatocytes; therefore, the compound with the structure as shown in the formula I has potential as a component of anti-hepatic fibrosis drugs.

The present application relates to the technical field of medicine, and provides application of Ben Dung decoction in preparation of medicine for treating ovarian cancer, wherein the Ben Dung decoction is prepared from licorice, Szechuan lovage rhizome, Chinese angelica, pinellia, radix scrophulariae, radix puerariae, radix paeoniae, ginger and root white bark of prunus mira koehne with a mass ratio of (1.5-2.5):(1.5-2.5):(1.5-2.5):(3-5):(1-3):(6-10):(1.5-2.5):(3-5):(4-7). The Ben Dung decoction can significantly affect the morphology and cycle of ovarian cancer ES-2 and OV-1063 cells, effectively inhibit the malignant phenotypes such as proliferation, migration, infiltration and cloning of the ovarian cancer ES-2 and OV-1063 cells, and inhibit the expression level of CA125 and CEA proteins in the ovarian cancer OV-1063 cells.

The invention relates to staphylococcus epidermidis fermentation liquor as well as a preparation method and application thereof, and belongs to the technical field of microbial fermentation. The invention provides a staphylococcus epidermidis fermentation broth with anti-inflammatory, anti-oxidation and whitening effects, staphylococcus epidermidis is a skin probiotic, a preparation method of the fermentation broth comprises the step of fermenting the staphylococcus epidermidis by using a fermentation medium containing glycerol or glucose, the content of the glycerol or the glucose is 10-50g / L, and the content of the staphylococcus epidermidis is 10-50g / L. The fermentation medium also contains beef extract, peptone and sodium chloride. The prepared staphylococcus epidermidis fermentation broth can effectively inhibit the expression level of inflammatory factors in cells, reduce ROS fluorescence intensity and MDA content, improve SOD enzyme activity, inhibit melanin synthesis and inhibit tyrosinase activity, can be applied to preparation of anti-inflammatory, anti-oxidation and whitening products, and has a wide application prospect.

The invention provides application of a circ-UBE2I RNA sequence in preparation of a medicine for inhibiting or treating glioma and the medicine, and application of the circ-UBE2I RNA sequence in preparation of the medicine for inhibiting or treating glioma, the nucleotide sequence of the circ-UBE2I RNA sequence is as shown in SEQ ID No.1, the circ-UBE2I RNA sequence can effectively inhibit glioma cells from forming blood vessels to generate vascular mimicry, and the circ-UBE2I RNA sequence can effectively inhibit glioma cells from forming blood vessels to generate vascular mimicry. Therefore, the vascular mimicry is inhibited from participating in transportation of blood, oxygen and nutrient substances of tumor tissues, and the effect of inhibiting glioma or improving the survival rate of patients is achieved.